Gastrointestinal Stromal Tumor (GIST) Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, and Treatment Outlook | Key Companies – Jiangsu Hengrui (Famitinib), Novartis (Nilotinib), Theseus (THE-630), Daiichi Sankyo (DS 6157), Ascentage (HQP1351), Advenchen (AL3818), Array Biopharma/Pfizer (Binimetinib), Taiho Oncology (TAS-116), Arog Pharma (Crenolanib)

PRESS RELEASE
Published February 7, 2023

Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, about 25+ key pharma and biotech companies are working on 28+ pipeline drugs in the Gastrointestinal Stromal Tumor therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Gastrointestinal Stromal Tumor (GIST) therapeutics market is anticipated to grow in the coming years owing to the increasing incident population of GIST patients along with the rise in awareness and disease understanding and the launch of emerging therapies.

Gastrointestinal Stromal Tumor (GIST) Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Gastrointestinal Stromal Tumor Market.

The Gastrointestinal Stromal Tumor Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Gastrointestinal Stromal Tumor (GIST) Pipeline Analysis
The report provides insights into:
– The report provides detailed insights about emerging therapies for the treatment of Gastrointestinal Stromal Tumor and the aggregate therapies developed by major pharma companies.
– It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gastrointestinal Stromal Tumor Treatment.
– It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
– The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
– It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Gastrointestinal Stromal Tumor market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Delveinsight’s Report Covers Emerging Products Under Different Phases of Clinical Development Like –
– Late-stage products (Phase III)
– Mid-stage products (Phase II)
– Early-stage products (Phase I/II and Phase I)
– Pre-clinical and Discovery stage candidates
– Discontinued & Inactive candidates

Route of Administration:
Gastrointestinal Stromal Tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
– Oral
– Parenteral
– Intravenous
– Subcutaneous
– Topical

Molecule Type:
Products have been categorized under various Molecule types, such as
– Monoclonal Antibody
– Peptides
– Polymer
– Small molecule
– Gene therapy

Mechanism of Action (MOA) of the Emerging Pipeline Therapies:
– Antibody-dependent cell cytotoxicity
– Phosphotransferase inhibitors
– Bcr-abl tyrosine kinase inhibitors
– TYK2 kinase inhibitors
– Fms-like tyrosine kinase 3 inhibitors
– Proto oncogene protein c-kit inhibitors

Gastrointestinal Stromal Tumor (GIST) Therapeutics Landscape

There are approx. 25+ key companies developing therapies for Gastrointestinal Stromal Tumors. Currently, Jiangsu Hengrui Medicine is leading the therapeutics market with its Gastrointestinal Stromal Tumors drug candidates in the most advanced stage of clinical development.

Some of the key companies in the Gastrointestinal Stromal Tumor (GIST) Therapeutics Market include:
Jiangsu Hengrui Medicine, Daiichi Sankyo Company, Cogent Biosciences, Advenchen Laboratories, Chia Tai Tianqing Pharmaceutical Group, AB Science, Immunicum AB, Novartis, Bristol-Myers Squibb, Hanmi Pharmaceutical Company Limited, GlaxoSmithKline, Ascentage Pharma, Takeda, Array BioPharma, Plexxikon, Arog Pharmaceuticals, Xencor, Inc., DNAtrix, Inc., Onyx Pharmaceuticals, Exelixis, Allarity Therapeutics, Theseus Pharmaceuticals, IDRx, Inc., Allarity Therapeutics, and many others.

Gastrointestinal Stromal Tumor (GIST) Therapies covered in the report include:
– Famitinib: Jiangsu Hengrui Medicine
– Nilotinib: Novartis
– THE-630: Theseus Pharmaceuticals
– DS 6157: Daiichi Sankyo Company
– HQP1351: Ascentage Pharma Group Inc.
– AL3818: Advenchen Laboratories
– Binimetinib: Array Biopharma/Pfizer
– TAS-116: Taiho Oncology
– Crenolanib: Arog Pharmaceuticals
And many more

Explore More About the Emerging Drugs and Key Companies: Gastrointestinal Stromal Tumor Pipeline Development Activities

Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Gastrointestinal Stromal Tumor Current Treatment Patterns
4. Gastrointestinal Stromal Tumor – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Gastrointestinal Stromal Tumor Late-Stage Products (Phase-III)
7. Gastrointestinal Stromal Tumor Mid-Stage Products (Phase-II)
8. Gastrointestinal Stromal Tumor Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Gastrointestinal Stromal Tumor Discontinued Products
13. Gastrointestinal Stromal Tumor Product Profiles
14. Key Companies in the Gastrointestinal Stromal Tumor Market
15. Key Products in the Gastrointestinal Stromal Tumor Therapeutics Segment
16. Dormant and Discontinued Products
17. Gastrointestinal Stromal Tumor Unmet Needs
18. Gastrointestinal Stromal Tumor Future Perspectives
19. Gastrointestinal Stromal Tumor Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Get a Detailed Assessment into the Ongoing Clinical and Regulatory Development Activities, at: Gastrointestinal Stromal Tumor Therapeutic Outlook

Contact Info:
Shruti Thakur
Manager (Marketing and Branding)
Email: info@delveinsight.com
https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Newsmantraa